Tanya Lewis
Vermogen: - $ op 31-05-2026
Vermogen: - $ op 31-05-2026
Tanya N.
Lewis is currently an Independent Director at DiaMedica Therapeutics, Inc. since 2023 and a Director at Sernova Biotherapeutics, Inc. Former roles include Chief Development Operations Officer at Replimune Group, Inc. from 2021 to 2024; Chief Regulatory & Quality Officer, Executive VP at Karyopharm Therapeutics, Inc. from 2019 to 2021; Vice President-Regulatory & Quality Affairs at Syros Pharmaceuticals, Inc. from 2017 to 2018; VP-Regulatory Affairs & Quality Assurance at Idera Pharmaceuticals, Inc. from 2015 to 2016; VP-Regulatory Affairs & Quality Assurance at Tesaro, Inc. from 2011 to 2015; Senior Director-Regulatory Affairs at Millennium Pharmaceuticals, Inc. in 2008; and VP-Regulatory Affairs & Quality Assurance at both Vion Pharmaceuticals, Inc. and Seaside Therapeutics LLC.
Education includes graduate studies at Massachusetts College of Pharmacy & Health Science and undergraduate studies at Northeastern University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 22-05-2026 | 0 ( -.--% ) | - $ | 31-05-2026 | |
| 01-06-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| DIAMEDICA THERAPEUTICS INC. | Directeur/Bestuurslid | 01-03-2023 |
| SERNOVA BIOTHERAPEUTICS INC | Directeur/Bestuurslid | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| REPLIMUNE GROUP, INC. | Directeur/Bestuurslid | 01-05-2021 |
| KARYOPHARM THERAPEUTICS INC. | Algemeen Adviseur | 01-05-2021 |
| SYROS PHARMACEUTICALS, INC. | Algemeen Adviseur | 01-07-2018 |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Algemeen Adviseur | 01-12-2016 |
| TESARO INC | Algemeen Adviseur | 01-06-2015 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 12 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops small molecule anticancer compounds | Health Technology |
Sernova Biotherapeutics, Inc.
Sernova Biotherapeutics, Inc. BiotechnologyHealth Technology Develops life science products | Health Technology |
DiaMedica Therapeutics, Inc.
DiaMedica Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of therapeutic treatments from novel recombinant proteins | Health Technology |
Tesaro, Inc.
Tesaro, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for cancer patients | Health Technology |
Massachusetts College of Pharmacy & Health Science
Massachusetts College of Pharmacy & Health Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seaside Therapeutics LLC
Seaside Therapeutics LLC Medical DistributorsDistribution Services Develops drug treatments to correct or improve the course of fragile x syndrome | Distribution Services |
Karyopharm Therapeutics, Inc.
Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which developing care for the frontline treatment of patients with hematologic malignancies | Health Technology |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau